Difference between revisions of "Thiotepa (Thioplex)"
m (→References) |
m |
||
| Line 10: | Line 10: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Bladder cancer]] | *[[Bladder cancer]] | ||
| + | *[[CNS lymphoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 31: | Line 32: | ||
[[Category:Bladder cancer medications]] | [[Category:Bladder cancer medications]] | ||
| + | [[Category:Central nervous system (CNS) lymphoma medications]] | ||
[[Category:Drugs FDA approved in 1959]] | [[Category:Drugs FDA approved in 1959]] | ||
Revision as of 02:35, 27 February 2015
Also known as TESPA, Thiophosphoamide, or TSPA.
General information
Class/mechanism: Alkylator, ethylenimine-type, similar to nitrogen mustards. Ethylenimine radicals are released, which alkylates at the N7 position of guanine, resulting in the linkage between the purine and sugar being severed, and subsequent cell damage and death.[1][2]
Route: IV, intravesicular, intracavitary; (off-label: IT)
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Thiotepa (Thioplex) patient drug information (Chemocare)[3]
- Thiotepa (Thioplex) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 3/9/1959: Initial FDA approval